Proactive Investors - Run By Investors For Investors

PreveCeutical Medical receives second Aurora cannabis shipment

The pot materials will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research...
PreveCeutical Medical receives second Aurora cannabis shipment
The materials from the shipment will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research

PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) has received the second shipment of dried cannabis materials from major Aurora Cannabis, it told investors.

The pot materials will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research.

As revealed in March, the company, in a major milestone, had received the key permits to allow this material to be imported into Australia by the  cannabis major.

It is being used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.

Preveceutical aims to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.

The advantages of Sol-gels over conventional liquid nasal sprays include reduced dosage requirements, and reduced irritation and other negative side effects.

Shares were unchanged at C$0.29.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

Laboratory testing
October 09 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
medical cannabis
September 30 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
1540909388_Marijuana-stethoscope.jpg
October 30 2018
The firm wants to become the first publicly listed, globally focused, pure cannabis company
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use